These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 35983926)

  • 1. Atogepant for migraine.
    Bedrin K; Ailani J
    Drugs Today (Barc); 2022 Aug; 58(8):399-405. PubMed ID: 35983926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atogepant: an emerging treatment for migraine.
    Rustichelli C; Avallone R; Ferrari A
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
    Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update of Gepants in the Treatment of Chronic Migraine.
    Cho S; Kim BK
    Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic characterization of atogepant: A potent and selective calcitonin gene-related peptide receptor antagonist.
    Moore E; Bell IM; Fraley ME; Burgey CS; White RB; Li CC; Regan CP; Danziger A; McGaraughty SP; Naseri Kouzehgarani G; Salvatore C; Banerjee P
    Cephalalgia; 2024 Jan; 44(1):3331024231226186. PubMed ID: 38215228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atogepant: Mechanism of action, clinical and translational science.
    Boinpally R; Shebley M; Trugman JM
    Clin Transl Sci; 2024 Jan; 17(1):e13707. PubMed ID: 38266063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR; da Silva MRR
    Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive Treatment of Migraine.
    Lipton RB
    Continuum (Minneap Minn); 2024 Apr; 30(2):364-378. PubMed ID: 38568488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gepants - a long way to cure: a narrative review.
    Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F
    Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atogepant: First Approval.
    Deeks ED
    Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atogepant (Qulipta®) for migraine prevention.
    Hay DL; Walker CS; Harris PWR
    Trends Pharmacol Sci; 2022 Aug; 43(8):701-702. PubMed ID: 35469689
    [No Abstract]   [Full Text] [Related]  

  • 13. Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.
    Singh A; Balasundaram MK
    Clin Drug Investig; 2022 Apr; 42(4):301-308. PubMed ID: 35230651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
    Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
    Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacotherapeutic management of episodic and chronic migraine with gepants.
    Tajti J; Szok D; Csáti A; Vécsei L
    Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries.
    Rubio-Beltran E; Chan KY; Danser AJ; MaassenVanDenBrink A; Edvinsson L
    Cephalalgia; 2020 Apr; 40(4):357-366. PubMed ID: 31674221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on gepants for the treatment of chronic migraine.
    Aoh Y; Hou TW; Yang CC; Chang CM; Chen SP; Tsai IJ; Cheng CW; Yang CP
    J Chin Med Assoc; 2024 Apr; 87(4):350-356. PubMed ID: 38349136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model.
    Thaliffdeen R; Yu A; Rascati K
    Clin Drug Investig; 2024 Mar; 44(3):209-217. PubMed ID: 38381352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial.
    Lipton RB; Nahas SJ; Pozo-Rosich P; Bilchik T; McAllister P; Finnegan M; Liu Y; Chalermpalanupap N; Dabruzzo B; Dodick DW
    J Headache Pain; 2024 May; 25(1):83. PubMed ID: 38773375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atogepant for the Preventive Treatment of Migraine.
    Ailani J; Lipton RB; Goadsby PJ; Guo H; Miceli R; Severt L; Finnegan M; Trugman JM;
    N Engl J Med; 2021 Aug; 385(8):695-706. PubMed ID: 34407343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.